A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
about
Tumor-Associated Macrophages as Target for Antitumor Therapy.High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrenceInvolvement of platelet-derived growth factor ligands and receptors in tumorigenesis.The role of macrophage phenotype in regulating the response to radiation therapy.
P2860
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A phase 2 multimodality trial ...... r after radical prostatectomy.
@en
type
label
A phase 2 multimodality trial ...... r after radical prostatectomy.
@en
prefLabel
A phase 2 multimodality trial ...... r after radical prostatectomy.
@en
P2093
P2860
P356
P1476
A phase 2 multimodality trial ...... er after radical prostatectomy
@en
P2093
A J Armstrong
B F Koontz
D J George
Department of Defense Prostate Cancer Clinical Trials Consortium
P2860
P2888
P304
P356
10.1038/PCAN.2015.59
P577
2016-01-12T00:00:00Z
P5875
P6179
1024178270